Cargando…
Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
Relapsed/refractory (rel/ref) acute myeloid leukemia (AML) has a very high mortality rate. At present, hematopoietic stem cell transplantation (HSCT) is the most effective treatment for rel/ref AML. The remission of the primary disease before HSCT is crucial for the transplantation to be effective....
Autores principales: | Lv, Wenxiu, Chen, Tianping, Wang, Shen, Li, Chun, Zhang, Bo, Wang, Liang, Xv, Fang, Cao, Fang, Wang, Jing, Chen, Li, Liao, Chenglin, Li, Na, Liu, Hongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982438/ https://www.ncbi.nlm.nih.gov/pubmed/36873635 http://dx.doi.org/10.3389/fped.2023.1117988 |
Ejemplares similares
-
Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia
por: Wang, Liang, et al.
Publicado: (2021) -
Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023) -
Subaru HDS (High Dispersion Spectrograph) Workshop: toward the First Light of HDS
Publicado: (1997) -
Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023) -
Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022)